Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 42, 2014, Pages E4504-E4512

  Lin, Yuan ^a   Zhang, Haipeng ^a   Liang, Jiankai ^a   Li, Kai ^a   Zhu, Wenbo ^a   Fu, Liwu ^b   Wang, Fang ^b   Zheng, Xiaoke ^c   Shi, Huijuan ^c   Wu, Sihan ^a   Xiao, Xiao ^a   Chen, Lijun ^a   Tang, Lipeng ^a   Yan, Min ^a   Yang, Xiaoxiao ^a   Tan, Yaqian ^a   Qiu, Pengxin ^a   Huang, Yijun ^a   Yin, Wei ^a   Su, Xinwen ^a   Hu, Haiyan ^c   Hu, Jun ^a   Yan, Guangmei ^a   more..

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Personalized medicine; Translational inhibition; Unfolded protein response

Indexed keywords

ONCOLYTIC VIRUS; ZINC FINGER PROTEIN; CASPASE;

ALPHA VIRUS; ALPHA VIRUS M1; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL KILLING; CELL SPECIFICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; ENDOPLASMIC RETICULUM STRESS; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIROTHERAPY; TISSUE MICROARRAY; VIRAL TROPISM; VIRUS REPLICATION; VIRUS STRAIN; ALPHAVIRUS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; CELL SURVIVAL; CLASSIFICATION; ENDOPLASMIC RETICULUM; GENE EXPRESSION PROFILING; METABOLISM; NEOPLASMS; PROCEDURES; RNA INTERFERENCE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

ALPHAVIRUS; ANIMALS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; ENDOPLASMIC RETICULUM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM TRANSPLANTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RNA INTERFERENCE; TISSUE ARRAY ANALYSIS; ZINC FINGERS;

EID: 84908077930     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1408759111     Document Type: Article

References (47)

1. Jemal A, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90.
2. Liu TC, Galanis E, Kirn D (2007) Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 4(2):101-117.
3. Miest TS, Cattaneo R (2014) New viruses for cancer therapy: Meeting clinical needs. Nat Rev Microbiol 12(1):23-34.
4. Sinkovics JG, Horvath JC (2008) Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 56(Suppl 1):3s-59s.
5. Stojdl DF, et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6(7):821-825.
6. Balachandran S, Porosnicu M, Barber GN (2001) Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 75(7):3474-3479.
7. Cheema TA, et al. (2013) Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cellmodel. Proc Natl Acad Sci USA 110(29):12006-12011.
8. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30(7):658-670.
9. Drake CG, Lipson EJ, Brahmer JR (2014) Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 11(1):24-37.
10. Hu J, Cai XF, Yan G (2009) Alphavirus M1 induces apoptosis of malignant glioma cells via downregulation and nucleolar translocation of p21WAF1/CIP1 protein. Cell Cycle 8(20):3328-3339.
11. Wen JS, et al. (2007) Genomic analysis of a Chinese isolate of Getah-like virus and its phylogenetic relationship with other Alphaviruses. Virus Genes 35(3):597-603.
12. Fukunaga Y, Kumanomido T, Kamada M (2000) Getah virus as an equine pathogen. Vet Clin North Am Equine Pract 16(3):605-617.
13. Strauss JH, Strauss EG (1994) The alphaviruses: Gene expression, replication, and evolution. Microbiol Rev 58(3):491-562.
14. Zhai YG, et al. (2008) Complete sequence characterization of isolates of Getah virus (genus Alphavirus, family Togaviridae) from China. J Gen Virol 89(Pt 6):1446-1456.
15. Wu J, Kaufman RJ (2006) From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ 13(3):374-384.
16. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D (2000) Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2(6):326-332.
17. Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8(7):519-529.
18. Ventoso I, et al. (2006) Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: A strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev 20(1):87-100.
19. Ferri KF, Kroemer G (2001) Organelle-specific initiation of cell death pathways. Nat Cell Biol 3(11):E255-E263.
20. Oyadomari S, MoriM (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11(4):381-389.
21. Nakagawa T, et al. (2000) Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403(6765):98-103.
22. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375-386.
23. Burke CW, Gardner CL, Steffan JJ, Ryman KD, Klimstra WB (2009) Characteristics of alpha/beta interferon induction after infection of murine fibroblasts with wild-type and mutant alphaviruses. Virology 395(1):121-132.
24. Naik S, Russell SJ (2009) Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 9(9):1163-1176.
25. Pecora AL, et al. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20(9):2251-2266.
26. Zhang Y, Burke CW, Ryman KD, Klimstra WB (2007) Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J Virol 81(20):11246-11255.
27. Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57.
28. Bick MJ, et al. (2003) Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol 77(21):11555-11562.
29. Guo X, Ma J, Sun J, Gao G (2007) The zinc-finger antiviral protein recruits the RNA processing exosome to degrade the target mRNA. Proc Natl Acad Sci USA 104(1):151-156.
30. Zhu Y, Wang X, Goff SP, Gao G (2012) Translational repression precedes and is required for ZAP-mediated mRNA decay. EMBO J 31(21):4236-4246.
31. Cheng C, et al. (2012) Enhancing chemosensitivity in ABCB1- and ABCG2-over-expressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202. Mol Pharm 9(7):1971-1982.
32. Furukawa T, Kubota T, Hoffman RM (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1(3):305-311.
33. Wein LM, Wu JT, Kirn DH (2003) Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: Implications for virus design and delivery. Cancer Res 63(6):1317-1324.
34. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282(5392):1332-1334.
35. Stojdl DF, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4(4):263-275.
36. Müller S, et al. (2007) Inhibition of filovirus replication by the zinc finger antiviral protein. J Virol 81(5):2391-2400.
37. Gao G, Guo X, Goff SP (2002) Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 297(5587):1703-1706.
38. Zhu Y, Gao G (2008) ZAP-mediated mRNA degradation. RNA Biol 5(2):65-67.
39. Buijs PR, van Eijck CH, Hofland LJ, Fouchier RA, van den Hoogen BG (2014) Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther 21(1):24-30.
40. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA (2010) Intelligent design: Combination therapy with oncolytic viruses. Mol Ther 18(2):251-263.
41. Mahoney DJ, et al. (2011) Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 20(4):443-456.
42. Beug ST, et al. (2014) Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 32(2):182-190.
43. Hermiston TW, Kuhn I (2002) Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 9(12):1022-1035.
44. Tseng JC, et al. (2004) Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 22(1):70-77.
45. Frolova E, et al. (2006) Formation of nsP3-specific protein complexes during Sindbis virus replication. J Virol 80(8):4122-4134.
46. Sun C, Gardner CL, Watson AM, Ryman KD, Klimstra WB (2014) Stable, high-level expression of reporter proteins from improved alphavirus expression vectors to track replication and dissemination during encephalitic and arthritogenic disease. J Virol 88(4):2035-2046.
47. Lee SY, et al. (2006) Preliminary study of chemosensitivity tests in osteosarcoma using a histoculture drug response assay. Anticancer Res 26(4B):2929-2932.